In one preclinical BC study, the combination of a microcavitating mechanical FUS regimen with anti-PD-L1 (anti–programmed death-ligand 1) was observed to significantly enhance the antitumor response, characterized by increased populations of CD4+ T cells, CD8+ T cells, and NK cells. The gene discussed is CD8A; the disease is breast cancer.